Last month, when Moderna released preliminary data on a phase 1 trial of its coronavirus vaccine, the early signs of success made headlines and sent the company's stock price soaring. But Dr. Anthony Fauci of the National Institute of Allergy and Infectious Diseases said that though the initial data from the company looks "very promising from the neutralizing antibody standpoint," he disapproved of how the company jumped to share the news before it had more data. "I didn't like that," Fauci told STAT News' Helen Branswell in an interview published Monday. "What we would have preferred to do, quite frankly,...